0
No hay productos en el carro de la compra
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Casa > Kits > VEGF165 > EP-137

VEGFA : VEGFR2 [Biotinylated] Inhibitor Screening ELISA Kit

For research use only.

Order Now

IDComponentsSize
EP137-C01High-bind Plate1 plate
EP137-C02Human VEGFA10 μg
EP137-C03Biotinylated Human VEGFR220 μg
EP137-C04Anti-VEGFA Neutralizing Antibody20 μg
EP137-C05Streptavidin-HRP10 μg
EP137-C06Coating Buffer12 mL
EP137-C0710xWashing Buffer 50 mL
EP137-C08Blocking Buffer50 mL
EP137-C09Substrate Solution12 mL
EP137-C10Stop Solution7 mL
  • Background
    Kinase insert domain receptor (KDR) is also known as CD309, FLK1, VEGFR, VEGFR2, and is one of the subtypes of VEGFR. VEGF receptors are receptors for vascular endothelial growth factor (VEGF). There are three main subtypes of VEGFR, numbered 1, 2 and 3. The VEGF receptors have an extracellular portion consisting of 7 immunoglobulin-like domains, a single transmembrane spanning region and an intracellular portion containing a split tyrosine-kinase domain. VEGF-A binds to VEGFR-1 (Flt-1) and VEGFR-2 (KDR/Flk-1). VEGFR-2 appears to mediate almost all of the known cellular responses to VEGF.The function of VEGFR-1 is less well defined, although it is thought to modulate VEGFR-2 signaling. Another function of VEGFR-1 may be to act as a dummy/decoy receptor, sequestering VEGF from VEGFR-2 binding (this appears to be particularly important during vasculogenesis in the embryo). In addition, VEGFR2 is able to interact with HIV-1 extracellular Tat protein upon VEGF activation, and seems to enhance angiogenesis in Kaposi's sarcoma lesions.
  • Application

    This kit is developed for screening for inhibitors of human VEGFA binding to human VEGFR2.

    It is for research use only.

  • Reconstitution
    Please see Certificate of Analysis for details of reconstitution instruction and specific concentration.
  • Storage
    Unopened kit should be stored at 2°C-8°C upon receiving. Find the expiration date on the outside packaging and do not use reagents past their expiration date.

    The opened kit should be stored per components table. The shelf life is 30 days from the date of opening.

  • Assay Principles
    This inhibitor screening ELISA kit is designed to facilitate the identification and characterization of new VEGFA pathway inhibitors. The assay takes advantage of our in house-developed binding of biotinylated human VEGFR2 to immobilized human VEGFA in a functional ELISA assay, and employs a simple colorimetric ELISA platform. Briefly, we provide you with a human Biotinylated VEGFR2 protein, a human VEGFA protein, an anti-VEGFA neutralizing antibody (as method verified Std.), and Streptavidin-HRP reagent.

    Your experiment will include 4 simple steps:

    a) Coat the plate with human VEGFA.

    b) Add your molecule of interest to the tests.

    c) Add human VEGFR2-Biotin to bind the coated VEGFA.

    d) Add Streptavidin-HRP followed by TMB or other colorimetric HRP substrate.

    Finally, the half maximal inhibitory concentration (IC50) of your compound to VEGFA: VEGFR2 binding will be determined by comparing OD readings among different experimental groups.

Typical Data Please refer to Ds document for the assay protocol.
 VEGF165 TYPICAL DATA

INHIBITION OF VEGFA: VEGFR2 [Biotinylated] BINDING BY ANTI-VEGF NEUTRALIZING ANTIBODY
Serial dilutions of Anti-VEGFA Neutralizing antibody (Catalog # EP137-C04) (1:1 serial dilution, from 10 μg/mL to 0.01953125μg/mL) was added into VEGFA: Biotinylated VEGFR2 binding reactions. The assay was performed according to the protocol described below. Background was subtracted from data points prior to log transformation and curve fitting (QC tested).

  • Clinical and Translational Updates

Comments (0)


ETA de productos en stock: 2 días laborables

Price(EUR) : €660.00

Promotion & Exhibitions



Drug Development Status

  • Number of Launched Drugs:40 Details
  • Number of Drugs in Clinical Trials:63 Details
  • Latest Research Phase:Approved

Datasheet & Documentation

Request for DMF
DMF (Drug Master File)

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

totop
Email
Correo electrónico
Fax
Fax
+1 888-377-6111
Address
Address
Lichtstrasse 35,4056 Basel, Switzerland

Dejar un mensaje